(Yicai Global) Jan. 21 -- Dongcheng Biochemicals plans to join hands with Japan's Nihon Medi-Physics to develop radioactive imaging technologies and medicine.
Dongcheng penned an agreement regarding an initial cooperation intention with Nihon, the Shandong province-based firm said in a statement on Jan. 18.
The pair will research and develop single-photon emission and positron emission tomography, as well as nuclear medicine. The Chinese firm said that there is still some uncertainly in terms of materializing the deal into a contract.
Upon completion, the partnership would expand Dongcheng's product portfolio, industry chains, and foster new profit growth, according to the statement. Nuclear medicine is the focus of the firm's business development strategy for the next 10 years, according to its website.
Tokyo's Nihon, a joint venture between Sumitomo Chemical and Chicago-based GE Healthcare, occupies about 70 percent of the Japanese radioactive medicine market.
Editor: Emmi Laine